/ Print /

LATEST

Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
State medical marijuana laws continue to expandMedical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Creating a ‘robust’ specialty pharmacy networkThe correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
Five ways tech can help close healthcare gapsIt’s no surprise that gaps in the screening, monitoring, and management of chronic diseases abound, even in managed care settings. Here’s how technology can help.
Insulin treatment persistence varies among payersA study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
How to target high-risk populations with behavioral healthHere are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.
Start MACRA reporting with a HIPAA risk assessment, or don’t start at allHere are five key security risk assessment elements to identify and remediate.